Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212257 | 1.00 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL26699378 | 1.00 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL14678926 | 0.85 | HCAR2 (0.48) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL27761598 | 0.83 | GAA (0.48) | HCAR2KEAP1NFE2L2MGAMGAA | |
| SCHEMBL13405605 | 0.83 | MAPT (0.50) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL869080 | 0.82 | TSHR (0.53) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL869082 | 0.82 | TSHR (0.53) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL821076 | 0.82 | TSHR (0.53) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL14287527 | 0.81 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2TSHRCYP4F2 | |
| SCHEMBL19730845 | 0.81 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| EP-4584243-B1 | CROSSLINKERS | HEMOTEQ AG (DE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4584244-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584243-A1 | CROSSLINKERS | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584245-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2025056815-A1 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | HEMOTEQ AG (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-20090012166-A1 | Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These | PLT PATENT & LICENSE TRADING S.L. (ES) | 2009-01-08 | — | — | US | disclosed |
| EP-1913090-B1 | SULFONIUM INITIATORS, PROCESS FOR PRODUCTION AND USE IN CATIONIC POLYMERIZABLE COMPOSITIONS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080200585-A1 | Sulfonium Initiators, Process For Production And Use In Cationic Polymerizable Compositions | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2008-08-21 | — | — | US | disclosed |
| EP-1913090-A1 | SULFONIUM INITIATORS, PROCESS FOR PRODUCTION AND USE IN CATIONIC POLYMERIZABLE COMPOSITIONS | 3M Innovative Properties Company (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070054139-A1 | Ionomer laminates, composite articles, and processes for making the same | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007016295-A1 | SULFONIUM INITIATORS, PROCESS FOR PRODUCTION AND USE IN CATIONIC POLYMERIZABLE COMPOSITIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1748057-A1 | Sulfonium initiators, process for production and use in cationic polymerizable compositions | 3M Innovative Properties Company (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-4660580-A | PREFERENTIAL; LIQUID AQUEOUS PRETREATMENT; IMMISCIBLE WITH PERMANENT WAVE SOLUTION | WELLA AKTIENGESELLSCHAFT (DE) | 1987-04-28 | — | — | US | disclosed |
| US-4024272-A | Tetracyclic compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012166-A1 | Oligomers of Straight-Chain and Unbranched Fatty Acids and Drugs Containing These | FASN, FFAR3, FFAR2 | HCAR2 26/4885KEAP1 3223/4885NFE2L2 2816/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | HCAR2 1906/4885KEAP1 1567/4885NFE2L2 2154/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | HCAR2 877/4885KEAP1 970/4885NFE2L2 1588/4885 |
| US-20080200585-A1 | Sulfonium Initiators, Process For Production And Use In Cationic Polymerizable Compositions | KCNH1, KCNH3, CCNH | HCAR2 2452/4885KEAP1 3232/4885NFE2L2 3938/4885 |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | HCAR2 3720/4885KEAP1 2195/4885NFE2L2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.